### AGENDA

**WEDNESDAY, NOVEMBER 18TH (STROKE CENTER DAY)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:10 ET</td>
<td>Welcome to SVIN 2020 - Virtual Experience / Platform &amp; Overall Remarks</td>
</tr>
<tr>
<td>10:10 - 10:15 ET</td>
<td>Welcome to Stroke Center Day</td>
</tr>
<tr>
<td>10:15 - 11:45 ET</td>
<td>Pre-Hospital Systems of Care</td>
</tr>
<tr>
<td>11:45 - 12:15 ET</td>
<td>Industry Symposium</td>
</tr>
<tr>
<td>12:15 - 12:30 ET</td>
<td>Break</td>
</tr>
<tr>
<td>12:30 - 14:00 ET</td>
<td>Acute Care</td>
</tr>
<tr>
<td>14:00 - 14:30 ET</td>
<td>RACECAT Trial Results &amp; Panel Discussion</td>
</tr>
<tr>
<td>17:00 - 17:30 ET</td>
<td>Women in Vascular and Interventional Neurology Reception</td>
</tr>
<tr>
<td>17:30 - 18:30 ET</td>
<td>Members in Training Reception</td>
</tr>
</tbody>
</table>

**THURSDAY, NOVEMBER 19TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:05 ET</td>
<td>Day Two Highlights</td>
</tr>
<tr>
<td>10:05 - 11:20 ET</td>
<td>Debates</td>
</tr>
<tr>
<td>11:20 - 11:35 ET</td>
<td>Business Meeting / Presidential Address</td>
</tr>
<tr>
<td>11:35 - 12:05 ET</td>
<td>Industry Symposium</td>
</tr>
<tr>
<td>12:05 - 12:20 ET</td>
<td>Break</td>
</tr>
<tr>
<td>12:20 - 13:40 ET</td>
<td>Endovascular + Vascular Neurology Joint Session 1</td>
</tr>
<tr>
<td>18:00 - 19:00 ET</td>
<td>SVIN 2020 Welcome Reception</td>
</tr>
</tbody>
</table>

**FRIDAY, NOVEMBER 20TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:05 ET</td>
<td>Day Three Highlights</td>
</tr>
<tr>
<td>10:05 - 11:30 ET</td>
<td>Aneurysm</td>
</tr>
<tr>
<td>11:30 - 12:00 ET</td>
<td>Industry Symposium</td>
</tr>
<tr>
<td>12:00 - 12:15 ET</td>
<td>Break</td>
</tr>
<tr>
<td>12:15 - 13:00 ET</td>
<td>Keynote Lecture: Egas Moniz – The Birth of Neuroangiography</td>
</tr>
</tbody>
</table>

**SATURDAY, NOVEMBER 21ST**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:05 ET</td>
<td>Day Four Highlights</td>
</tr>
<tr>
<td>10:05 - 11:20 ET</td>
<td>Endovascular + Vascular Neurology Joint Session 2</td>
</tr>
<tr>
<td>11:20 - 11:35 ET</td>
<td>Break</td>
</tr>
<tr>
<td>11:35 - 12:50 ET</td>
<td>Radial Access in Neuroangiography: Acquiring The Taste</td>
</tr>
<tr>
<td>12:50 - 15:15 ET</td>
<td>Fellows Course</td>
</tr>
</tbody>
</table>

### ON DEMAND CONTENT

- Stroke Center Continuum
- Nuts and Bolts of Running a Stroke Center
- NIR Sessions
  - Interventional Approaches: Beyond Stroke
  - Technical Nuances
- APP Sessions
  - Current and Evolving Approaches to Intravenous Thrombolysis
  - Ongoing Medical Management of Stroke
- Vascular Neurology Sessions
  - New Era of Acute Stroke Care
  - Stroke Prevention and Rehabilitation
- Platform Sessions
- Clinical Trials Update: Stroke and Neurointerventional
- SVIN / SNIS Joint Session - Management of Arteriovenous Malformations

*Agenda Subject to Change*
The Society of Vascular and Interventional Neurology (SVIN) welcomes you to its 13th Annual Meeting: SVIN 2020 Virtual Meeting. This year’s fitting theme is “Advancement and Innovation Despite Adversity.”

These challenging times allow for unprecedented opportunities. While meetings have always been in the spirit of providing inspiration and education, it would be a disservice to ignore the important values of an in-person Annual Meeting, as they allowed for networking and provided the ideal environment to totally immerse yourself in the experience. Given the current pandemic, we are navigating new waters with our first ever virtual Annual Meeting. This year’s Annual Meeting Committee has made a conscious effort to pay homage to our conference tradition, while giving space for the new trends brought forth by the new world order and attempting to optimize interactions through a sophisticated virtual platform.

SVIN’s innate multidisciplinary and diverse nature is substantiated by the continued participation of physicians from varied specialties, advanced practice providers, neuroscientists, nurses, administrators, and industry collaborators across the globe. The conference will encompass established sessions with live content in addition to providing on-demand content.

SVIN 2020 starts with live content for Stroke Center Day, covering the spectrum from pre-hospital management to rehabilitation, as well as the administrative aspects of running a stroke center. Other live topics throughout the meeting include the Joint Vascular Neurology & Neurointerventional, Cerebral Aneurysm, and Radial Angiography sessions, as well as the Fellow’s Course. This format maintains the value of our traditional conference, allowing scientists with different backgrounds to be brought together and substantiating SVIN’s commitment in educating the next generation, but in a virtual fashion.

Additionally, on-demand content will incorporate Vascular Neurology, Neurointerventional, and Advanced Practice Provider tracks, Clinical Trial Updates, as well as a highly anticipated joint session on Arteriovenous Malformations to be held in conjunction with the Society of Neurointerventional Surgery (SNIS). Original research will be promoted through interactive virtual oral platforms and posters.

While the COVID-19 pandemic is an evident theme in shaping the conference, it may not be so obvious that we should make the conscious choice to view the positive outcomes from this crisis. Instead of being immobilized, we have decided to actively seek content and strategies to mitigate the repercussions of adversity.

The Annual Meeting Committee, Fundraising Committee, SVIN’s Board of Directors, and Executive Committee would like to invite you to join us at #SVIN2020. Finally, we would like to thank our meeting sponsors for their continued support of the SVIN Annual Meeting and encourage you to visit the virtual exhibit hall. Without the support of our industry partners, meetings such as this one would not be possible.

Together we will advance and innovate the cerebrovascular field despite adversities.

Diogo C. Haussen, MD, FSVIN
Chair, 13th Annual SVIN Meeting & At-Large Board Member
TABLE OF CONTENTS

General Information ................................................................. 4
CME/CE Information ............................................................... 5
Program ..................................................................................... 7
On Demand ............................................................................... 13
Faculty ..................................................................................... 20
Awards and Recognitions ...................................................... 23
Exhibitor Listing ..................................................................... 25
About SVIN ............................................................................... 27
GENERAL INFORMATION

SVIN 13TH ANNUAL MEETING PROGRAM DESCRIPTION
This year’s Annual Meeting continues to reflect the diversity, innovation, and creativity of our rapidly growing membership and our international partners. We look forward to an exciting meeting, which aims to address some of the most controversial issues confronting our field today. We have an excellent program this year that will pay homage to the traditional meeting format while adapting to honor the SVIN’s essence of innovation despite the current adversities.

On our first day, Dr. Jawad Kirmani will chair our Stroke Center Day focusing on stroke systems of care and hospital infrastructure. National leaders in the field of stroke will share essential lessons learned on a broad range of topics that drive quality stroke center operations. Topics will include new protocols and technologies for organizing pre-hospital care, successful practices for optimizing your ED and interventional suite, stroke center certification insights from the pros, harnessing the power of your EMR, optimizing stroke center finances, emerging artificial intelligence-based technologies, clinical research infrastructure and many more. This programming is intended to bring together hospital administrators, EMS providers, physicians, nurses, coordinators, technologists, and other stroke champions from primary and comprehensive stroke centers. Ample time for discussions and questions will assure a robust exchange of information about world-class stroke practice.

The remainder of the meeting includes tracks geared towards Neurointerventionalists, Vascular Neurologists, Advanced Practice Providers and Neurohospitalists. The new format allows us to capture the latest insights and developments from both U.S. and international thought leaders in the Interventional, Nursing, and Vascular Neurology fields. A highly expected novel session is the joint event between the SVIN and the Society of Neurointerventional Surgery (SNIS) on arteriovenous malformations. The fellows’ course and the members in training reception will provide a great environment for professional development of trainees. Our sophisticated platform and the virtual social events will keep our members connected and continue to foster networking and long-term friendships typically created at our Annual Meeting.
Upon completion of the educational activity, participants should be able to:

- Describe evidence-based treatment approaches for structural hemorrhages, intraparenchymal hemorrhage, and acute ischemic stroke
- Discuss key elements of a workup to determine pathogenic mechanism for patients with acute stroke
- Improve processes on stroke operations from the ED to angiography suite
- Strengthen the ability to build a comprehensive stroke program
- Optimize technical performance of stroke, aneurysm, AVM and neurointerventions
- Discuss emergent applications of neuroangiography/intervention
- Discuss the future of Interventional Neurology and the International barriers to Stroke Treatment
- Discuss key elements of a workup to determine pathogenic mechanism for patients with acute stroke
- Describe evidence-based treatment approaches for structural hemorrhages, intraparenchymal hemorrhage and acute ischemic stroke
- Identify expanded roles and scholarship opportunities to increase advanced practice provider influence

Faculty and Planner Disclosures

<table>
<thead>
<tr>
<th>NAME</th>
<th>RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Abbott, A/Prof (MBBS, PhD)</td>
<td>Research</td>
<td>Research funding from the National Health and Medical Research Council Australia (NHMRC)</td>
</tr>
<tr>
<td>Heinrich Audebert, MD</td>
<td>Consultant and Speaker</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Avandil Babanashvili, PhD</td>
<td>Speaker</td>
<td>Abbott Vascular, Biosensors International, Siemens</td>
</tr>
<tr>
<td>Waleed Briniæi, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Joseph Broderick, MD</td>
<td>Consultant</td>
<td>Ono Pharmaceuticals</td>
</tr>
<tr>
<td>Bruce Campbell, MBBS BMedSc PhD FRACP</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Andrew Carlson, MD, MS-CR</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Saruhan, Cekirge, MD</td>
<td>Consultant</td>
<td>Medtronic, Microvention</td>
</tr>
<tr>
<td>Rene Chapot, MD, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Michael Chan, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Tom Devlin, MD, PhD, FSVIN</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Lucas Eljovich, MD, FAHA, FSVIN</td>
<td>Consultant</td>
<td>Balt, Microvention, Scientia Vascular, Stryker</td>
</tr>
</tbody>
</table>

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Please visit https://akhcme.com/akhcme/pages/ svin. You must participate in the entire activity to receive credit. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Society of Vascular and Interventional Neurology. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses

AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is awarded 11 contact hours. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and the Society of Vascular and Interventional Neurology.

EARN UP TO 16.25 hrs of credit for completing the On-Demand!

Earn up to 27.25 hr of cme/ce credit for completing all of the live and on demand content
### FACULTY DISCLOSURE

<table>
<thead>
<tr>
<th>NAME</th>
<th>RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clay Johnston, MD, PhD</td>
<td>Advisor</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Tudor Jovin, MD, FSVIN</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Christopher Kellner, MD</td>
<td>Research</td>
<td>Cerebrotech, Minnetronix, Integra, Penumbra, Viz.AI</td>
</tr>
<tr>
<td>Priyank, Khandelwal, MD</td>
<td>Grant</td>
<td>Stryker</td>
</tr>
<tr>
<td>Jawad Kimani, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Thabele (Bay) Leslie Mazvi, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Michael Levit, MD</td>
<td>Consulting</td>
<td>Medtronic</td>
</tr>
<tr>
<td>David Liabseking, MD</td>
<td>Consultant</td>
<td>Cereonov, Genentech, Medtronic, Stryker</td>
</tr>
<tr>
<td>Birjosh, Mehta, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Howie Mell, MD, MPH, FACEP</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>J. Mocco, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Max Mokin, MD</td>
<td>Stock</td>
<td>Endostream, Serenity Medical, Stryker, VICIS</td>
</tr>
<tr>
<td>Sandra Narayanan, MD, FAHAFAANA, FSVIN</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Victor Oliveira, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN</td>
<td>Consultant</td>
<td>Medtronic, Stryker Neurovascular</td>
</tr>
<tr>
<td>Mark Parsons, B.Med (UCN) PhD (UCM),FRACP (Neurology), FAAHMS</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Marios Psychogios, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Radoslav Raychev, MD, FAHAFAHA</td>
<td>Consultant</td>
<td>NeuroVasc, Pernflor Medical, Rapid Medical, Spartan Micro</td>
</tr>
<tr>
<td>Eytan Raz, MD, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Nures Sasosann, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Wouter Schonewille, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Magdy Selim, MD, PhD</td>
<td>Advisory Board/Consultant</td>
<td>MedRhythms, Inc.</td>
</tr>
<tr>
<td></td>
<td>Research Grants</td>
<td>NNHNNDS Royalty Cambridge University Press</td>
</tr>
</tbody>
</table>

### FACULTY DISCLOSURE

<table>
<thead>
<tr>
<th>NAME</th>
<th>RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adnan Siddiqui, MD, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>AKH and SVIN Planners and Reviewers</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
</tbody>
</table>

### PLANNER DISCLOSURES

<table>
<thead>
<tr>
<th>NAME</th>
<th>RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOWIE MELL, MD, MPH, FACEP</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>J. MOCO, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>CLAY JOHNSTON, MD, PHD</td>
<td>Advisor</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>TUDOR JOVIN, MD, FSVIN</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>MAGDY SELIM, MD, PHD</td>
<td>Advisory Board/Consultant</td>
<td>MedRhythms, Inc.</td>
</tr>
<tr>
<td>MARK PARSONS, B.MED (UCN) PhD (UCM),FRACP (Neurology), FAAHMS</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>MARIOS PSYCHOCHIOS, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>RADOSS LAW RAYCHEV, MD, FAHA</td>
<td>Consultant</td>
<td>NeuroVasc, Pernflor Medical, Rapid Medical, Spartan Micro</td>
</tr>
<tr>
<td>EYTA RAZ, MD, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>NURES SASOANN, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>WOUTER SCHONEWILLE, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>ADNAN SIDDQUI, MD, PHD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>DILIP YAVAGAL, MD</td>
<td>Consultant</td>
<td>CereneousDeck Therapeutics, Deck Therapeutics, Guidepoint Consulting, Medtronic, Neuroanalytics, Poseyson Medical, LLC, Rapid Medical (Member of Clinical Trial Steering Committee for SWIFT-Prime), VascularDynamics</td>
</tr>
</tbody>
</table>

### Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The Society of Vascular and Interventional Neurology (SVIN) and AKH, Inc., Advancing Knowledge in Healthcare specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participation in this course.

### Disclosure Declaration

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

<table>
<thead>
<tr>
<th>NAME</th>
<th>RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. David Spence, MD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Matthew Whalin, MD, PhD</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Osama (Saim) Zaidat, MD, FSVIN</td>
<td>N/A</td>
<td>Nothing to disclose</td>
</tr>
</tbody>
</table>

### Commercial Support

There is no support for this activity.

### Disclosure of Unlabeled Use and Investigational Product

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The Society of Vascular and Interventional Neurology (SVIN) and AKH, Inc., Advancing Knowledge in Healthcare specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participation in this course.
## PROGRAM

ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE

### WEDNESDAY, NOVEMBER 18

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:10</td>
<td>Welcome to SVIN 2020 - Virtual Experience / Platform &amp; Overall Remarks (Non-CME)</td>
<td>Diogo C. Haussen, MD, FSVIN</td>
</tr>
<tr>
<td>10:10 – 10:15</td>
<td>Welcome to Stroke Center Day</td>
<td>Jawad Kirmani, MD, FSVIN</td>
</tr>
<tr>
<td>10:15 – 11:45</td>
<td>Pre-Hospital System of Care</td>
<td>Jawad Kirmani, MD, FSVIN and Martin Gizzi, MD, PhD</td>
</tr>
<tr>
<td></td>
<td><strong>Debate: Mobile Stroke Unit - Illusions of Hope or Hope for Desillusion (Mobile Stroke Unit: The Present &amp; the Future)</strong></td>
<td>Heinrich Audebert, MD</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 10:45</td>
<td><strong>Debate: Mobile Stroke Unit - Illusions of Hope or Hope for Desillusion (Mobile Stroke Unit: Illusion or Reality?)</strong></td>
<td>Howard Mell, MD, MPH, FACEP</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Field LVO Detection - Ready for Primetime?</td>
<td>Christopher Kellner, MD</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>PreHospital Communication Tech Tools - The Golden Era</td>
<td>Brijesh Mehta, MD</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Therapeutics in the Field - Hit When It’s Hot (Non-CME)</td>
<td>Joseph Broderick, MD</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
12:15 – 12:30 Break

12:30 – 14:00 Acute Care
Moderators: Jawad Kirmani, MD, FSVIN & Magdy Selim, MD, PhD

12:30 – 12:45 IV Thrombolysis Options - A Broadening or Constricting Horizon?
Bruce Campbell, MBBS BMedSc PhD, FRACP

12:45 – 13:00 IV Thrombolysis Before Thrombectomy?
Urs Fischer, MD, MSc

13:00 – 13:15 Direct to Angiography - Optimizing Logistics
Marios Psychogios, MD

13:15 – 13:30 Neuroscience Service Line Integration
J Mocco, MD

Clay Johnston, MD, PhD

13:45 – 14:00 Q&A

14:00 – 14:30 RACECAT Trial Results & Panel Discussion

17:00 – 17:30 Women in Vascular and Interventional Neurology Reception

17:30 – 18:30 Members in Training Reception

THURSDAY, NOVEMBER 19

10:00 – 10:05 Day Two Highlights
Diogo C. Haussen, MD, FSVIN

10:05 – 11:20 Debates
Moderators: Dileep Yavagal, MD, FSVIN & Sam Zaidat, MD, FSVIN

10:05 – 10:15 Debate 1: Suspected COVID LVO: General Anesthesia FirstLine
Claus Simonsen, MD

10:15 – 10:25 Debate 1: Suspected COVID LVO: Sedation FirstLine
Matthew Whalin, MD, PhD

10:25 – 10:35 Early Window Thrombectomy Imaging Debate: CT and CTA: Do the Right Thing
Thabele (Bay) Leslie-Mazwi, MD

10:35 – 10:45 Early Window Thrombectomy Imaging Debate: Stroke Scale and Flat Panel CT: The Inorexible Future
Marc Ribo, MD

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:45 – 10:55 | **Late Window Thrombectomy Imaging Debate:** Advanced Imaging (CTP/MRI): Stick With The Evidence  
Mark Parsons, B.Med (UON) PhD (UOM), FRACP (Neurology), FAAHMS |
| 10:55 – 11:05 | **Late Window Thrombectomy Imaging Debate:** NCCT: Stop Overselecting  
Tudor Jovin, MD, FSVIN                                           |
| 11:05 – 11:20 | **Q&A**                                                              |
| 11:20 – 11:35 | **Business Meeting / Presidential Address**                         
David Liebeskind, MD, FAHA, FAAN, FSVIN                          |
| 11:35 – 12:05 | **Industry Symposium with Stryker: Optimizing Patient Outcomes Through Next Generation Technology**  
Moderator: Ameer E. Hassan, DO, FAHA, FSVIN                      |
| 11:35 – 11:50 | **FPE Matters. TrevoNXT & Trak21 Take Thrombectomy to the Next Level**  
Satoshi Tateshima, MD, DMSc                                      |
| 11:50 – 12:05 | **64 Wire Surpass Evolve, a New Class in Flow Diversion**            
Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN                  |
| 12:05 – 12:20 | **Break**                                                            |
| 12:20 – 13:40 | **Endovascular + Vascular Neurology Joint Session 1**               
(Stroke in the Era of COVID-19)                                   
Moderators: Thomas Devlin, MD, PhD, FSVIN & Michael Chen, MD     |
| 12:20 – 12:30 | **Clinical Manifestations & Pathophysiology of COVID+ Stroke**       
James Seigler, MD                                                  |
| 12:30 – 12:40 | **Expansion of Telehealth/Telemedicine in the COVID Era**            
Mike Frankel, MD                                                   |
| 12:40 – 12:50 | **Lessons Learned From the Pandemic: Preparedness of Stroke Care During Natural Disasters & Non-Emergent Care**  
Johanna Fifi, MD, FSVIN                                           |
| 12:50 – 13:00 | **Q&A**                                                              |
|              | **Endovascular + Vascular Neurology Joint Session 1**               
(Posterior Circulation Stroke)                                     |
|              | **Posterior Circulation Ischemia: Diagnosis, Workup, Predictors of Recurrence**  
Nerses Sanossian, MD                                               |
Wouter Schonewille, MD

13:20 – 13:30  Vertebral Origin Disease and Subclavian Stenosis: Indications and Treatment Options  
Santiago Ortgea-Gutierrez, MD, MSc, FAHA, FSVIN

13:30 – 13:40  Q&A

18:00 – 19:00  SVIN 2020 Welcome Reception

FRIDAY, NOVEMBER 20

10:00 – 10:05  Day Three Highlights  
Diogo C. Haussen, MD, FSVIN

10:05 – 11:30  Aneurysms  
Moderators: Maxim Mokin, MD & Lucas Elijovich, MD, FAHA, FANA, FSVIN

10:05 – 10:15  To Treat or Not to Treat? Predictors of Aneurysm Rupture - Do We Have a Crystal Ball?  
Michael Levitt, MD

10:15 – 10:25  Kid in a Candy Store: So Many Flow Diverters - Which One to Choose?  
Saruhan Cekirge, MD

10:25 – 10:35  Wide Neck Aneurysms - Should We Continue Using Balloon-Assisted Coiling?  
Rene Chapot, MD, PhD

10:35 – 10:45  AI in Diagnosing and Treating Aneurysms  
Waleed Brinjikji, MD

10:45 – 10:55  Optimal Follow Up After Aneurysm Treatment - How Often and When to Stop?  
Nitin Goyal, MD

10:55 – 11:05  Treatment of Vasospasm - The Never-Ending Battle?  
Andrew Carlson, MD, MS-CR, FAANS

11:05 – 11:30  Q&A

11:30 – 12:00  Industry Symposium with Medtronic  
Moderator: Mario Alegre

11:30 – 11:45  Early Experience Using AI Powered Telehealth in a Hub & Spoke System  
Ameer E. Hassan, DO, FAHA, FSVIN

11:45 – 12:00  A Step Forward in Reperfusion with React  
Bradley Gross, MD
12:00 – 12:15 Break

12:15 – 13:00 Keynote Lecture
  12:15 – 12:20 Introduction
     Camilo Gomez, MD, MBA
  12:20 – 13:00 Egas Moniz - The Birth of Neuroangiography
     Victor Oliveira, PhD

SATURDAY, NOVEMBER 21

10:00 – 10:05 Day Four Highlights
     Diogo C. Haussen, MD, FSVIN

10:05 – 11:20 Endovascular + Vascular Neurology Joint Session 2 (Atherosclerotic Disease Controversy)
     Moderators: M. Shazam Hussain, MD & Radoslav Raychev, MD, FAHA
  10:05 – 10:15 Biomarkers to Predict Higher Risk ICAD
     Mitch Elkind, MD, MS
  10:15 – 10:25 Management In-Situ Thrombosis LVOS
     Fazeel Siddiqui, MD, FAHA
     David Spence, MD
  10:35 – 10:45 Asymptomatic Carotid Disease Debate: It is a New Era of Non-Invasive Intervention
     Anne Abbott, MBBS, PhD
  10:45 – 10:55 Higher Risk Features in Carotid Stenting
     Adnan Siddiqui, MD, PhD
  10:55 – 11:05 TCAR: What’s the Evidence
     Brian Jankowitz, MD
  11:05 – 11:20 Q&A

11:20 – 11:35 Break

11:35 – 12:50 Radial Access in Neuroangiography: Acquiring The Taste
     Moderators: Mikayel Grigoryan, MD & Ameer E. Hassan, DO, FAHA, FSVIN
  11:35 – 11:45 Historical Overview of Radial Access
     Mikayel Grigoryan, MD
  11:45 – 11:55 Radial Setup and Diagnostic Angiography
     Priyank Khandelwal, MD
  11:55 – 12:05 Learning Curve, Tips and Tricks
     Ameer E. Hassan, DO, FAHA, FSVIN

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05 – 12:15</td>
<td>Neurointervention Using Radial Access</td>
<td>Pascal Jabbour, MD</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>Complications in Radial Access</td>
<td>Eytan Raz, MD, PhD</td>
</tr>
<tr>
<td>12:35 – 12:50</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:50 – 15:15</td>
<td>Fellows Course</td>
<td></td>
</tr>
<tr>
<td>12:50 – 13:15</td>
<td>Surpass Evolve™ Flow Diverter: 64 Wire Flow Diversion and Deployment Technique</td>
<td>Ajay Wakhloo, MD, PhD, FAHA</td>
</tr>
<tr>
<td>13:15 – 13:40</td>
<td>Starting a CSC and How to Work With Industry to Grow Your Program</td>
<td>Ameer E. Hassan, DO, FAHA, FSVIN</td>
</tr>
<tr>
<td>13:40 – 14:05</td>
<td>Sofia Aspiration Catheter and Mechanical Thrombectomy: Tips &amp; Tricks</td>
<td>Syed Zaidi, MD</td>
</tr>
<tr>
<td>14:05 – 14:30</td>
<td>Choose Your Next Adventure: Algorithm for Owning Your Stroke and Aneurysm Practice</td>
<td>Ashish Nanda, MD</td>
</tr>
<tr>
<td>14:30 – 14:45</td>
<td>The Clinical Utility of Dual Lumen Balloons</td>
<td>Lucas Elijovich, MD, FAHA, FSVIN</td>
</tr>
<tr>
<td>14:45 - 15:15</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Stroke Center Continuum
Host: Amer Malik, MD, MBA, FSVIN, FAHA

- Is It Time to Step Up Our Stroke Units?
  Andrei Alexandrov, MD, NVS

- Role of Neurohospitalist Within Continuum of Stroke Care
  Andrew Josephson, MD

- Advances in Neurocardiology
  Shadi Yaghi, MD

- Express Outpatient Triage TIA’s and Minor Strokes
  Shelagh Coutts, MD

- Innovations to Advance Recovery
  Steven Cramer, MD

Nuts and Bolts of Running a Stroke Center
Host: David Liebeskind, MD, FAHA, FAAN, FSVIN

- How to Navigate The Certification Process
  Joseph Schindler, MD

- Clinical Research and Beyond - How Do You Leverage Your Existing Telestroke System
  Lawrence Wechsler, MD

- Administrative Perspective on Making a Successful Stroke Center
  Russel Starkey, MBA

- Optimizing Patient Care Post Discharge
  Cheryl Bushnell, MD, MHS

- Quality Improvement
  Karen Seagraves, PhD, MPH, NEA-BC, APRN, FAHA

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
Vascular Neurology: New Era of Acute Stroke Care
Host: Nirav Bhatt, MD

The Cutting Edge: Surgical and Medical Management of ICH
Wendy Ziai, MD, MPH

Reversal of Oral Anticoagulants
Jeffrey Weitz, MD, FRCP, FRSC, FACP

Does Size and Composition Matter? Implications of Thrombus Characteristics in Lysis
Andrew Demchuk, MD

Revising and Refining the Stroke Workup
Ashutosh Jadhav, MD, PhD, FSVIN

Deep Into the Brain: Artificial Intelligence in Stroke Care
Soojin Park, MD, FAHA, FNCS

Avoiding Hemicraniectomy: Medical Management of Malignant MCA Stroke
Taylor Kimberly, MD, PhD

Vascular Neurology: Stroke Prevention and Rehabilitation
Host: Giselle Sampaio-Silva, MD, MPH, PhD

Anticoagulants After Hemorrhagic Stroke
Edip Gurol, MD, MSc

New Approaches in the Treatment of Hypertension
Paul Whelton, MB, MD, MSc

Dyslipidemia Management: How Low is Low Enough?
Seemant Chaturvedi, MD

Impact of COVID on Acute Revascularization and Protocols
Thanh Nguyen, MD, FSVIN

Role of Neuroprotection in Stroke: What the Future Holds
Michael Hill, MD, MSc, FRCP

Microbiome and Stroke
Louise McCullough, MD, PhD

Genetics of Stroke
Chia-Ling Phuah, MD, MMSc

Cerenovus On-Demand Clot Workshop
Platform Session I

Host: Alicia Castonguay, PhD, FSVIN

RNA Expression Identifying Ischemic Stroke In Acute Hospital Setting: Interim Analysis From BASE Clinical Trial
Daniel Miller, MD

Closely Sizing the Catheter to Vessel Enables Flow-Arrest and Flow-Reversal During Aspiration in the MCA
Raul Nogueria, MD, FSVIN

Long-term Sided Branch and Perforator Patency Following Surpass Flow ‘Diverter Treatment in the SCENT Trial
Miklos Marosfoi, MD

Acute Stroke Management of Tandem Oclusions During Mechanical Thrombectomy Survey
Cynthia Zevallos, MD

Motor Neuroprosthesis Implanted Using Cerebral Venography Improves Activities of Daily Living in Severe Paralysis
Thomas Oxley, MD, PhD

No Delay in Care of Acute Stroke Due to the COVID19 Pandemic: The SVIN Collaboration
James Sielger, MD

Platform Session II

Host: Alicia Castonguay, PhD, FSVIN

Safety and Efficacy of Intra-arterial Mesenchymal Stem Cell Therapy in a Canine Model of Stroke
Roshni Thakkar, PhD

Thrombectomy with a Novel Device: Initial Experience with a Catheter Featuring a Self- Expanding Funnel
Marc Ribó, MD

Prospective Post-Market Safety Study Of The Apollo Microcatheter For Onyx Embolization Of Brain Arteriovenous Malformations
Johanna Fifi, MD, FSVIN

Safety and Efficacy of the Penumbra System for Large Vessel Occlusion Thrombectomy: The COMPLETE Registry
Sam Zaidat, MD, FSVIN

Neuroform Atlas™ Stent Assisted Posterior Circulation Aneurysm Coiling: Primary Outcomes
Brian Jankowitz, MD

Stroke Etiologies in Patients with COVID-19: The SVIN COVID-19 Multinational Registry
Maria Ramos-Araque, MD, PhD

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
NIR Session: Interventional Approaches: Beyond Stroke
Host: Italo Linfante, MD, FSVIN, FAHA

Intra-Arterial Therapy for Brain Tumors: A Neurologist’s Perspective
Alexandra Czap, MD

Intra-Arterial Therapy for Brain Tumors: A Neurosurgeon’s Perspective
Peter Kan, MD, MPH

Venous Stenting for IIH and PT
Nima Aghaebrahim, MD

Endovascular Neuromodulation
Sunil Sheth, MD, FSVIN

Intra-Arterial Therapy for Headaches
Adnan Qureshi, MD

NIR Session: Technical Nuances
Host: Robin Novakovic-White, MD, FSVIN, FAHA

Carotid Stenting: Managing Restenosis
Alex Abou-Chebl, MD, FSVIN

Determination of Ischemic Core: Optimizing CT, CTA and CTP Reads
Steven Hetts, MD

Novel Thrombectomy Techniques and Technologies
Raul Nogueira, MD, FSVIN

What’s the Score? Optimizing TICI Grading
Albert Yoo, MD, PhD

Emergent Flow-Diversion: When, How, and Why?
Ricardo Hanel, MD, PhD

Non-Arterial Approaches to AVM and Fistula Embolization
Viktor Szeder, MD, PhD
APP: Current and Evolving Approaches to Intravenous Thrombolysis
Host: Alicia Richardson, MSN, ACCNS-AG, ANVP-BC, ASC-BC

- Pharmacokinetics and Pharmacodynamics of Thrombolytic Agents
  Samarth Shah, PharmD, BCPS

- Scientific Support for Alteplase and Tenecteplase Treatment of Ischemic Stroke (Non-CME)
  Anne Alexandrov, PhD, AGACNP-BC, ANVP-BC, NVRN-BC, CCRN, FAAN

- Prescribing and Administering Alteplase and Tenecteplase (Non-CME)
  Skye Coote, NP, MN

---

APP: Ongoing Medical Management of Stroke
Host: Rhonda Finnie, DNP, APRN, AGACNP-BC, ANVP-BC, ASC-BC

- Pharmacologic Management of Hyperlipidemia
  Samarth Shah, PharmD, BCPS

- Antiplatelets: Dual vs. Monotherapy: What to Prescribe When
  Justin Lowe, PA-C

- Indications and Anticoagulation Treatment Considerations
  Alicia Richardson, MSN, ACCNS-AG, ANVP-BC, ASC-BC

---

Clinical Trials Update: Stroke & Neurointerventional
Host: Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN

- Ischemic Stroke Prevention: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)
  Thomas Brott, MD

- Ischemic Stroke - Systems of Care: Triage-Stroke: Treatment Strategy In Acute Large Vessel Occlusion: Prioritize IV or Endovascular Treatment-A Randomized Trial
  Claus Simonsen, MD

- Ischemic Stroke - EVT Indications or Expansion: In Extremis: Laste / Moste
  Vincent Costalat, PU-PH

- Ischemic Stroke - EVT Indications or Expansion: SELECT 2 - A Randomized Controlled Trial to Optimize Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke
  Amrou Sarraj, MD, FAHA

- Ischemic Stroke - EVT Indications or Expansion: Basilar Artery Occlusion Chinese Endovascular Trial (BAOCHE)
  Tudor Jovin, MD, FSVIN

- Hemorrhagic Stroke: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)
  David Fiorella, MD, PhD
Joint SVIN-SNIS Session: Management of Arteriovenous Malformations
Host: Diogo C. Haussen, MD, FSVIN

Neuroimaging of Arteriovenous Malformations
Gregory Christoforidis, MD

Evidence-Based Multimodality Treatment of Brain Arteriovenous Malformations
Stavropoula Tjoumakaris, MD

Neurointerventional Treatment of Cerebral Arteriovenous Malformations following ARUBA
Phillip Meyers, MD

Optimizing Outcomes Using Radiosurgery for AVMs
L. Dade Lundsford, MD, FAC, FAANS

Micronavigation, Augmented Reality, and Heads-up Display as Surgical Adjuncts in AVM Surgery
Joshua Bederson, MD

Cerenovus On-Demand Symposium AVM Management:
The Case for TRUFILL n-BCA
Osama O. Zaidat, MD
Late Breaking & Pilot Grant Platform Session
Host: Alicia Castonguay, PhD, FSVIN

Pre-clinical Large Vessel Occlusion Stroke Model: Capybaras (Hydrochoerus Hydrochoeris)
Diogo C. Haussen, MD, FSVIN

Detection and Quantification of Symptomatic Atherosclerotic Plaques with High-Resolution Imaging in Cryptogenic Stroke
Rami Fakih, MD

Angiosuite Cone-Beam Computed Tomography Perfusion Imaging in Large Vessel Occlusion Thrombectomy Patients Using RAPID Software
Darko Quispe-Orozco, MD

Distal MCA M2 Thrombectomy in the STRATIS Registry
Mouhammad Jumaa, MD

Benefit of Mechanical Thrombectomy in the Excellent Registry – Interim Analysis
Amin Nima Aghaebrarhim, MD

Single-Center Experience with Endovascular Treatment of Cerebral Arteriovenous Malformations in Pediatric Patients
Aaron Rodriguez-Calienes, MD

The Society of Vascular and Interventional Neurology Registry (SVIN Registry): A Prospective Multicenter Thrombectomy Consortium
Diogo C. Haussen, MD, FSVIN

*ALL TIMES ARE REFLECTED IN EASTERN STANDARD TIME ZONE*
Christopher Kellner, MD
Mount Sinai Health System

Priyank Khandelwal, MD
University Hospital Rutgers, State University of New Jersey
W. Taylor Kimberly, MD, PhD
Massachusetts General Hospital

Jawad Kirmani, MD, FSVIN
JFK Medical Center

Thabele (Bay) Leslie-Mazwi, MD
Massachusetts General Hospital

Michael Levitt, MD
University of Washington

David Liebeskind, MD, FAHA, FSVIN
UCLA

Italo Linfante, MD, FAHA, FSVIN
Miami Neuroscience Institute Baptist Hospital

Justin Lowe, PA-C
Penn State Health Milton S. Hershey Medical Center

L. Dade Lundsford, MD, FAC, FAANS
University of Pittsburgh

Amer Malik, MD MBA FAHA FSVIN
University of Miami Miller School of Medicine

Miklos Marosfoi, MD
Beth Israel Lahey Health, LHMC

Louise McCullough, MD, PhD
McGovern Medical School at UTHealth

Brijesh Mehta, MD
Memorial Neuroscience Institute

Howie Mell, MD, MPH, FACEP
St. Louis University

Phillip Meyers, MD
Columbia University, Vagelos College of Physicians & Surgeons

Daniel Miller, MD
Henry Ford Hospital - Wayne State University

J Mocco, MD
Mount Sinai Health System

Maxim Mokin, MD
University of South Florida

Sandra Narayanan, MD, FSVIN
University of Pittsburgh School of Medicine

Thanh Nguyen, MD, FSVIN
Boston Medical Center

Raul Nogueira, MD, FSVIN
Memorial Hospital/ Emory University School of Medicine

Robin Novakovic-White, MD, FSVIN, FAHA
UT Southwestern Medical Center

Victor Oliveira, PhD
Dept Neurology Faculdade de Medicina - University of Lisboa Portugal

Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN
University of Iowa

Thomas Oxley, MD, PhD
University of Melbourne

Sooin Park, MD, FAHA, FNCS
Columbia University, New York Presbyterian Hospital

Mark Parsons, B.Med (UON) PhD (UOM), FRACP (Neurology), FAAHMS
University of New South Wales Sydney and Ingham Institute for Applied Medical Research

Chia-Ling Phauh, MD, MMSc
Washington University School of Medicine in St. Louis

Marios Psychogios, MD
University Hospital Basel

Darko Quispe-Orozco, MD
University Hospital of Salamanca. University Hospital of Valladolid. Spain.

Radoslav Raychev, MD, FAHA
St. Jude Medical Center

Eytan Raz, MD, PhD
NYU Langone Health

Marc Ribo, MD
Hospital Vall d’Hebron

Alicia Richardson, MSN, ACCNS-AG, ANVP-BC, ASC-BC
Penn State Health

Aaron Rodriguez-Calienes, MD
Facultad de Medicina Humana de la Universidad de San Martin de Porres

Gisele Sampaio-Silva, MD, MPH, PhD
UNIFESP/HIAE

NerseSanosssian, MD
University of Southern California

Amrou Sarraj, MD, FAHA
UT McGovern Medical School

Joseph Schindler, MD
Yale University School of Medicine

Wouter Schonewille, MD
St Antonius Hospital, Nieuwegein, the Netherlands

Karen B. Seagraves, PhD, MPH, NEA-BC, APRN, FAHA
Atrium Health

Magdy Selim, MD, PhD
Beth Israel Deaconess Medical Center / Harvard Medical School

Samarth P. Shah, PharmD, BCPS
University of Wisconsin

Sunil Sheth, MD, FSVIN
UTHealth McGovern Medical School

Adnan Siddiqui, MD, PhD
University at Buffalo Neurosurgery

Fazel Siddiqui, MD, FAHA
Metro Health University of Michigan

James Siegler, MD
Cooper Neurologic Institute, Cooper University Hospital, Camden, NJ

Claus Simonesen, MD
Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

J. Dade Spence, MD
Stroke Prevention & Atherosclerosis Research Centre, Roberts Research Institute, Western University, London, Canada

Russell Starkey, MBA
Hackensack Meridian Health System

Viktor Szeder, MD, PhD
UCLA University of California Los Angeles

Roshni Thakkar, PhD
NeuroEndovascular Division, Department of Neurology. Miller School of Medicine, University of Miami, Miami, FL.

Stavropoulou Tjoumakaris, MD
Thomas Jefferson University Hospital

Jeffrey Weitz, MD, FRCPC, FRSC, FACP
McMaster University

Lawrence Wechsler, MD
University of Pennsylvania

Matthew Whalin, MD, PhD
Emory University School of Medicine

Paul Whelton, MB, MD, MSc
Tulane University

Shadi Yaghi, MD
NYU Langone Health

Dileep Yavagal, MD, FSVIN
University of Miami/Jackson Health System

Albert Yoo, MD, PhD
Texas Stroke Institute

Sam Zaidat, MD, FSVIN
M Mercy Health

Cynthia Zevulnos, MD
University of Iowa

Wendy Ziai, MD, MPH
Johns Hopkins University School of Medicine
NON-EDUCATIONAL MATERIAL
AWARDS AND RECOGNITION

OFFICERS

President
David Liebeskind, MD, FAHA, FAAN, FSVIN

President Elect
Ameer E. Hassan, DO, FAHA, FSVIN

Immediate Past President
Italo Linfante, MD, FSVIN, FAHA

Secretary
Thanh Nguyen, MD, FSVIN

Treasurer
Ashutosh Jadhav, MD, PhD, FSVIN

Board of Directors
Steve M. Cordina, MD, FSVIN
Diogo C. Haussen, MD, FSVIN
Vallabh Janardhan, MD, FSVIN, FAHA, FAAN
Rakesh Khatri, MD, FSVIN
Ameer Malik, MD, MBA, FSVIN, FAHA
Ossama Mansour, MD, FNR, EBNRcet, FSVIN
Sandia Narayanan, MD, FSVIN
Robin Novakovic-White, MD, FAHA, FSVIN
Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN
Sunil Sheth, MD, FSVIN

Ex-Officio
Sam Zaidat, MD, FSVIN
Tudor Jovin, MD, FSVIN
Dileep Yavagal, MD, FSVIN
Raul Nogueira, MD, FSVIN

Executive Director
Jennifer Potter-Vig

2020 ANNUAL MEETING COMMITTEE

SVIN would like to thank the following individuals for their contribution to the SVIN 2020 Meeting:

Chair: Diogo C. Haussen, MD, FSVIN
Anne Alexandrov, PhD, AGACNP-BC, ANVP-BC, NVRN-BC, CCRN, FAAN
Nirav Bhatt, MD
Alcida Castonguay, PhD, FSVIN
Alexandra Czap, MD
Thomas Devlin, MD, PhD, FSVIN
Lucas Elijovich, MD, FAHA, FSVIN
Rhonda Finnie, DNP, APRN, AGACNP-BC, ANVP-BC, ASC-BC
Martin Gizzi, MD, PhD
Mikayel Grigoryan, MD
Natalie Hall, MSN, FNP-C, ANVP-BC
Ameer E. Hassan, DO, FAHA, FSVIN
Ashutosh Jadhav, MD, PhD, FSVIN
Jawad Kirmani, MD, FSVIN
Maxim Mokin, MD
Thanh Nguyen, MD, FSVIN
Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN
Alicia Richardson, MSN, ACCNS-AG, ANVP-BC, ASC-BC
Gisele Sampaio Silva, MD, MPH, PhD
UNIFESP/HIAE
Magdy Selim, MD, PhD
Sunil Sheth, MD, FSVIN

2020 Fundraising Committee Chair:
Ashutosh Jadhav, MD, PhD, FSVIN
Lucas Elijovich, MD, FAHA, FSVIN
Ameer E. Hassan, DO, FAHA, FSVIN
Tudor Jovin, MD, FSVIN
Raul Nogueira, MD, FSVIN
Dileep Yavagal, MD, FSVIN
Sam Zaidat, MD, FSVIN

2020 Abstract Committee Chair:
Alicia Castonguay, PhD, FSVIN
Michael Abraham, MD
Anthony Alvarado-Ortiz, MD
Fawaz Al-Mufti, MD
Lucas Elijovich, MD, FAHA, FSVIN
Diogo C. Haussen, MD, FSVIN
Italo Linfante, MD, FSVIN, FAHA
Ashutosh Jadhav, MD, PhD, FSVIN
Priyank Khandelwal, MD
Sonal Mehta, MD
Thanh Nguyen, MD, FSVIN
Robin Novakovic-White, MD, FSVIN, FAHA
Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN
Hisham Salahuddin, MD
Edgar Adres Samaniego, MD
Mohammed Teleb, MD

CONGRATULATIONS TO THE FOLLOWING SOCIETY Awardees:

SVIN 2020 Best Abstract Award
James Siegel, MD
No delay in care of acute stroke due to the COVID19 pandemic: The SVIN collaboration

SVIN 2020 Young Investigator Award
Cynthia Zevallos, MD
Acute Stroke Management of Tandem Occlusions During Mechanical Thrombectomy Survey
ENDORSEMENTS
The following organizations endorse the SVIN 13th Annual Meeting:

AMERICAN SOCIETY OF NEUROIMAGING
ASSOCIATION OF NEUROVASCULAR CLINICIANS
EUROPEAN SOCIETY OF MINIMALLY INVASIVE NEUROLOGICAL THERAPY
EUROPEAN STROKE ORGANISATION
SOCIETY OF NEUROINTERVENTIONAL SURGERY
WORLD STROKE ORGANIZATION

SVIN TOP SUPPORTERS
SVIN gratefully acknowledges the generous support from our sponsors:

DIAMOND LEVEL

GOLD LEVEL

SILVER LEVEL

BRONZE
ASAHI INTECC USA, Inc.
E: meiu.kou@asahi-intecc-us.com

ASAHI INTECC is a global manufacturer of micro guide wire technology. Asahi is in 108 countries and sells guide wires in the coronary and Neurovascular markets.

Balt USA
P: (949) 788-1443
W: https://balt-usa.com

For over 40 years, Balt has been a global leader in the innovation of novel products for the interventional access and treatment of neurovascular diseases. With one of the most comprehensive product portfolios available, Balt products are used around the world to access and treat multiple disease states including arterial venous malformations, aneurysms, and ischemic stroke.

CERENOVUS

CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, is a global leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.

Imperative Care

Understanding its vast and urgent needs, Imperative Care is singularly focused on finding meaningful answers to unsolved problems in stroke. With the goal of advancing interventional stroke care, we are focused on developing innovative catheter technologies that significantly improve interventional stroke treatment. Learn about TracStar LDP and the Zoom Stroke Solution at our virtual booth.
ISI: bit.ly/2Vx0Qcf

Medtronic
5290 California Ave
Irvine, CA 92617
P: (800) 633-8766
W: www.medtronicNV.com

Making healthcare better is our priority and we believe technology can play an even greater role in improving people’s lives. In addition to alleviating pain, restoring health, extending lives, we work in partnership with others to create seamless, more efficient care. Learn how we’re taking healthcare Further, Together at Medtronic.com.

MicroVention, Inc.
35 Enterprise
Aliso Viejo, CA 92656
E: cathy.demyanovich@microvention.com
W: www.microvention.com

MicroVention provides a complete approach to neuroendovascular technologies and currently consists of four main product groups: Aneurysm Therapy Solutions, Ischemic Stroke and Carotid Artery Disease Solutions, Neurovascular Malformation Solutions, and Access Product Solutions. Our extensive product lines allow our customers to provide a meaningful improvement in patients’ lives.

Penumbra, Inc.
E: info@penumbrainc.com
P: (510) 748-3200

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets.

Phenox Inc.
9842 Research Drive
Irvine, CA 92618
P: (844) 674-3669
E: cs@phenox.com
W: www.phenox.com/usa

Since its founding in 2005, Phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases. Phenox’s products are used by endovascular specialists to treat ischemic and hemorrhagic stroke. More information about the company and its products can be found at www.phenox.com.
Q’Apel Medical
46708 Lakeview Blvd
Fremont, CA. 94538
P: 510.738.6255
E: info@qapelmedical.com / orders@qapelmedical.com

Q’Apel Medical is a highly innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions and unmet clinical needs.

RAPID AI
405 El Camino Real, Suite 601
Menlo Park, CA 94025
P: (650) 388-9767
E: info@rapid.ai
W: www.rapid.ai

RAPID is the worldwide leader in advanced imaging for stroke. Installed in over 1,300 hospitals, RAPID (automated CTP, MRI, CTA and ASPECTS), with enhanced AI framework, is the only clinically-validated stroke imaging platform — RAPID response time, RAPID results, with custom notifications, on any mobile device. Easy, fast, secure.

Rapid Medical
1355 Shotgun Road
Sunrise, FL 33326
P: (954) 884-2120
E: infousa@rapid-medical.com
W: www.rapid-medical-us.com

Rapid Medical is committed to improving the treatment of stroke. The company’s Comaneci and Tigertriever products utilize a transformative 3D braiding technique that allows physicians to control device configurations during deployment. This unique technology improves how each device conforms to the vasculature across a broad range of anatomies.

Scientia

By adopting a first-principles approach, we collaborate with physicians to develop innovative medical devices and therapies that are unconstrained by conventional design and optimized to address the evolving needs of interventional specialists. Our next-generation solutions allow interventional specialists to expand what’s possible. To learn more, please visit us at www.scientiavascular.com

Stryker
47900 Bayside Parkway
Fremont, CA 94538
E: NVCustomerService@stryker.com
W: www.stryker.com

Stryker is one of the world’s leading mechanical technology companies and together with our customers, is driven to make healthcare better. We offer innovative products and services in Orthopedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.

Viz.ai
Viz.ai, 1819 Polk Street (293)
San Francisco, CA 94109
W: www.viz.ai
E: hello@viz.ai

Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.
Become a Member of **SVIN** Today!

The Society was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. SVIN is committed to fostering scientific research in the field of cerebrovascular diseases and neurointerventional procedures through internal and external collaboration with other groups.

**SVIN Membership Benefits include:**

- Discounted SVIN Meeting Rates
- Access to Member Directory
- Mentorship Program Participation
- Education & Career Planning
- Participation in National Taskforces
- Complimentary Job Postings
- Archival Materials from Past Meetings
- Voting Rights
- Networking Opportunities
- Patient & Research Information
- Volunteer Opportunities
- Advocacy and Counsel on Critical Care Issues
- Discounts on SVIN Meeting Rates
- Job Posting Discounts
- Access to The Core Newsletter

By joining SVIN, you become part of the premier organized body of Vascular and Interventional Neurology in the world!

Visit [www.svin.org](http://www.svin.org) for details on how to join or email us at [info@svin.org](mailto:info@svin.org).

---

**Apply for FSVIN!**

The Society of Vascular and Interventional Neurology (SVIN) offers an elevated member status of Fellow of Society of Vascular and Interventional Neurology (FSVIN), the SVIN’s esteemed category of membership. Fellow status recognizes exceptional service and contribution to the Society, academic excellence, and leadership in the field of Vascular and Interventional Neurology. Individuals who meet the requirements of this elevated membership status will add the letters, FSVIN, to their respective titles. You may become a Fellow of Society of Vascular and Interventional Neurology (FSVIN) using one of the following routes:

- **Active SVIN members** may apply for the FSVIN membership if they have attended at least 3 SVIN Annual Meetings and have been an SVIN member for a minimum of 5 years. Additional criteria and application information can be found on www.svin.org or provided upon request by emailing info@svin.org.

- **Current FSVIN members** may nominate Active members of SVIN for the fellow of SVIN status if the nominee meets the criteria outlined above and on www.svin.org.

- **SVIN Board of Directors members** are granted FSVIN membership due to their contributions of time, effort, and thoughtful leadership to the Society during their term(s) of service.

**Questions?** Please feel free to stop by the registration area where staff will be able to assist.

Visit [www.svin.org](http://www.svin.org) to apply online or submit your application.
Improving Stroke Outcomes

Stroke is the second leading cause of death worldwide.
Expand your knowledge to improve outcomes.

This online course includes:
• Basic Anatomy, Statistics, & Types of Strokes
• Risk Factors, Signs & Symptoms
• BE FAST, EMS, & Detection Scales
• Treatment Options & Methods for Improving Stroke Outcomes

To help expand the stroke treatment network, this course is geared towards:
• Physicians
• Nurses
• Emergency Medical Technicians
• First Responders
• Healthcare Workers
• Hospital Personnel
• General Public

Course Details
Price: $35 for SVIN members
$50 for non-members
Time: Self-paced, online course, approx. 1.5-2 hours
Accreditation: 1.5 ACCME, ANCC, CAPCE

If you have questions, please contact Delaney Hogan-Bakke at education@svin.org
Current stroke education and the understanding of stroke scales and regional protocols is paramount for the improved outcomes of stroke patients. Grow your stroke skills for use in the field!

This course will expand your knowledge on:
- Types of Stroke & Risk Factors
- Prehospital Triage
- Stroke Detection Scales
- Warning Signs & Symptom
- Stroke Severity Scales
- Treatment Options
- Bypass & Transfer Protocols

To help increase the stroke treatment network, this course is appropriate for:
- First Responders
- Emergency Medical Technicians
- Fire Fighters
- Police Officers
- Paramedics
- Nurses
- Physicians

Course Details
Price: $50 for SVIN members
$75 for non-members
Time: Self-paced course, approximately 2.5 hours
Certification: 2-year ASES certification of completion
Accreditation: 2.5 ACCME, ANCC, CAPCE
Access online course at svin.org
For questions, please contact Delaney Hogan-Bakke at education@svin.org

EMS is the first line of care for stroke patients.
Expand your knowledge to improve outcomes

Current stroke education and the understanding of stroke scales and regional protocols is paramount for the improved outcomes of stroke patients.

Grow your stroke skills for use in the emergency department!

**Course Details:**
- **Price:** $50 for SVIN members  
  $75 for non-members  
- **Time:** Self-paced course, approximately 2.5 hours  
- **Certification:** 2-year ASES certification of competition  
- **Accreditation:** 2.5 ACCME, ANCC, CAPCE  
- **Group Pricing:**  
  - 10-50 courses: 15% off individual rate  
  - 51-99 courses: 25% off individual rate  
  - 100+ courses: 50% off individual rate

Please visit svin.org for additional information regarding the new ASES ED course or contact Delaney Hogan-Bakke at education@svin.org with questions regarding any BSES or ASES online courses or to inquire about hosting a live course at your institution.
Follow Us on Social Media

SVIN - Society of Vascular and Interventional Neurology
https://www.facebook.com/SVINonline/
@Svinsociety

#SVIN2020

Here’s a few ways to connect with us via social media to submit a topic or start a discussion:

• Post, pin, like and share your annual meeting experience on FB
• Tweet, retweet, follow, and use #SVIN2020 on Twitter
• Invite us to your LinkedIn network
• Visit the Registration Desk to learn more
• Contact the SVIN Executive office at info@svin.org to share your success story or a patient testimonial.

GET INVOLVED WITH SVIN!

If you would like to get more involved with SVIN, please contact info@svin.org and indicate your area of interest!

Learn more at www.svin.org
JOIN THE WORLDWIDE MT2020 CAMPAIGN!

- A global effort to improve stroke care worldwide by increasing the rate of stroke thrombectomy for eligible patients from less than 100,000 procedures today to at least 202,000 annually by 2020 and thereby reducing global stroke, death and disability.
- Download the MT2020 mobile app and begin tracking your cases! Authorized Proxy can enter de-identified cases, track personal, local and global thrombectomy cases in real time.
- Visit the MT2020 website at: www.missionthrombectomy2020.org
- Contact info@svin.org with questions, or to find out how you or your organization can support MT2020!

MOBILE APP DOWNLOAD INSTRUCTIONS:
- Navigate your browser to mt2020.org
- Create a user account*
- Visit your app store and search for ‘mt2020’
- Download the MT2020 mobile app
- Log in using the credentials set up on your browser account

*SVIN members: Use the email address affiliated with your SVIN user account for expedited verification! Email support@mt2020.org for support help.

JOIN THE WORLDWIDE MT2020 CAMPAIGN!
The React™ 68 Catheter and React™ 71 Catheter feature a coil and braid design along with end-to-end Nitinol construction—easing navigation to the M1 and M2 segments.

Combine that with its compatibility across AIS devices—and it’s easy to see how React™ helps provide confidence with even your most challenging cases.

Compatible with Solitaire™ X Revascularization Device

Compatible with 6F long sheaths, Min ID of 0.087”

See React™ in action at medtronic.com/react

1. TR-NV15999 Rev B

CAUTION: Federal (USA) law restricts these devices to sale distribution and use by or on order of a physician. Indications, contraindications, warnings and instructions for use for Solitaire™ X Revascularization Device can be viewed at www.medtronic.com/manuals. Indications, contraindications, warnings and instructions for all other products can be found in the product labeling supplied with each device.

UC202103423 EN © 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 9775 Toledo Way, Irvine, CA 92618.
MicroVention Sponsored Symposiums During the SVIN Virtual Conference

**Wednesday, November 18 | 11:45am EST**

**BOBBY™ / SOFIA™ System: Development**

**Genesis of MicroVention’s Next Generation SOFIA™ Compatible Balloon Guide Catheter**

Jacques Dion, MD, FRCP(C), FSNIS
Vice President, Scientific Affairs
MicroVention, Inc.

**Fellows Course**

**Saturday, November 21 | 1:40pm EST**

**SOFIA™ Aspiration Catheter and Mechanical Thrombectomy: Tips & Tricks**

Syed F. Zaidi, MD
Associate Professor Neurology
Director of Neurointerventional Program
University of Toledo & Promedica Toledo Hospital
Toledo, OH

**Indications for Use:**

The BOBBY™ Balloon Guide Catheter is intended for use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel in the peripheral and neurovascular systems. The balloon provides temporary vascular occlusion during these and other angiographic procedures. The Balloon Guide Catheter is also intended for use as a conduit for retrieval devices.

The SOFIA™ Flow Plus Aspiration Catheter with the Gomco™ 405 Aspiration Pump and MicroVention™ Tubing Kit is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

MicroVention, BOBBY, Gomco, and SOFIA are registered trademarks of MicroVention, Inc. the United States and other jurisdictions • Refer to Instructions for Use, contraindications and warnings for additional information. © 2020 MicroVention, Inc. 10/2020.
When it’s go time, trust the versatility & reliability of the TriVecta™ Thrombectomy Platform

4 next generation devices designed for how you want to use them.

Go for the first pass
Trevo NXT ProVue Retriever & Trevo Trak 21 Microcatheter

Go bigger
AXS Vecta 74 Intermediate Catheter

Go farther
AXS Infinity LS Plus 91 Long Sheath

TriVecta Thrombectomy Platform
RX ONLY
See package insert for complete indications, contraindications, warnings and instructions for use.

Indications for use
AXS Infinity LS Plus Long Sheath: The AXS Infinity LS Plus Long Sheath is indicated for the introduction of interventional devices into the peripheral, coronary, and neurovasculature. AXS Vecta Intermediate Catheter: (1) The AXS Vecta Aspiration Catheter, as part of the AXS Vecta Aspiration System is indicated in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. (2) The AXS Vecta Intermediate Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems. The AXS Vecta Intermediate Catheter is also indicated for use as a conduit for retrieval devices. Trevo NXT ProVue Retriever: (1) The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should start within 6 hours of symptom onset. (2) The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. (3) The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA) with smaller core infarcts (0-50cc for age < 80 years, 0-20cc for age ≥ 80 years). Endovascular therapy with the device should start within 6-24 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy.

For Important Safety Information, please click the Learn More button.
Attend the CERENOVSUS SYMPOSIUM available ON DEMAND until November 28th

AVM MANAGEMENT: THE CASE FOR TRUFILL™ n-BCA

SPEAKER: Osama O. Zaidat, MD

- EXCELLENT Thrombectomy Registry Interim results (abstract)
- Balloon Guide vs. Intermediate Catheter in ARISE II (poster)
- First experience with Geometric Clot Extractor NIMBUS* (independent poster)

*NIMBUS approved in Europe not approved in US.
©CERENOVUS 2020. All rights reserved. 157324-201028
SVIN MEMBERS, OUR SINCERE APPRECIATION FOR ALL YOU HAVE DONE FOR STROKE CARE IN THIS MOST CHALLENGING 2020.
Surpass Evolve™ Flow Diverter System

RX ONLY See package insert for complete indications, contraindications, warnings and instructions for use. Intended use / indications for use: The Surpass Evolve Flow Diverter System is indicated for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width ≥ 4 mm or dome-to-neck ratio < 0.5) intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm and ≤ 5.0 mm. Contraindications: The Surpass Evolve Flow Diverter System is contraindicated in the following patient types: Patients in whom the parent vessel size does not fall within the indicated range. Patients in whom platelet and/or anticoagulation therapy (e.g., aspirin and clopidogrel) is contraindicated. Patients who have not received dual anti-platelet agents prior to the procedure. Patients with an active bacterial infection. Patients in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment due to conditions such as: Severe intracranial vessel tortuosity or stenosis; and/or Intracranial vasospasm not responsive to medical therapy. Potential adverse events: Risks that may be associated with the use of the Surpass Evolve Flow Diverter System in the intracranial arteries include: Adverse reaction to anesthesia, contrast or anticoagulant/anticoagulation agents; Anaphylaxis; Cardiac arrhythmias; Cranial neuropathy; Confusion, coma, change in mental status; Death. Device migration, fracture, misplacement. Dissection of the parent artery. Embolism (air, clot, device fragments); Graft injury (bleeding, pain, vessel/nerve damage); Headache; Hemiplegia; Hydrocephalus; Implant or parent vessel stenosis; Implant thrombosis/occlusion; Infection; Intracerebral bleeding; Mass effect; Myocardial infarction; Neurological deficits; Perforation or rupture of aneurysm; Perforation of Parent Artery; Progressive neurologic symptoms related to intracranial aneurysm (IA); Pseudoaneurysm formation; Reaction to radiation exposure (i.e., alopecia, bursa ranging in severity from skin reddening to ulcer, cataracts, delayed neoplastic; Renal failure; Retropertioneal hematoma; Seizure; Stroke; Subarachnoid hemorrhage; Thromboembolism from device; Thrombosis of parent artery or branch vessel; Transient ischemic attack (TIA); Vasospasm. Risks that are eye related with the use of the Surpass Evolve Flow Diverter System may include: Amaurosis fugax/transient blindness; Blindness; Diplopia; Reduced visual acuity/field; Retinal artery occlusion; Retinal ischemia; Retinal infarction; Vision impairment.

Warnings: Contents supplied STERILE using an ethylene oxide (EO) process. Do not use if sterile barrier is damaged. If damage is found, call your Stryker Neurovascular representative. For single patient use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death. Reuse, reprocessing or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease from one patient to another. Contamination of the device may lead to injury, illness or death of the patient. After use, dispose of product and packaging in accordance with hospital administrative and/or local government policy. This device should only be used with adequate fluoroscopic guidance by physicians who have received appropriate training in interventional neuroradiology or interventional radiology and training on the use of this device as established by Stryker Neurovascular. Persons allergic to nickel, cobalt chromium or platinum tungsten metal may suffer an allergic response to this system. Appropriate anti-platelet and anti-coagulation therapy should be employed in accordance with standard medical practice. [Clinical Warning] The safety and effectiveness of the device has not been evaluated or demonstrated for ruptured intracranial aneurysms. [Clinical Warning] A decrease in effectiveness has been observed in subjects aged > 65 years old, subjects with history of smoking and history of prior non-target intracranial aneurysm treatment. [Clinical Warning] Placement of multiple Surpass Evolve Flow Diverter Systems in the same vessel may increase the risk of ischemic complications. Implantation of more than one Surpass Evolve Flow Diverter System in non-clinical in vivo studies showed an increase in the generation of platinum microparticles in the surrounding vessel tissue. The presence of the platinum microparticles did not produce any adverse pathological changes such as: stent fragmentation or altered healing in the implanted vessels in the animals; however, the risk of platinum microparticulates in human patients is unknown. [Clinical Warning] Delayed aneurysm rupture may occur with large and giant intracranial aneurysms. Cautions / precautions: Carefully weigh the benefits of treatment vs. the risks associated with treatment using the device for each individual patient's medical condition and risks factors for intracranial aneurysm rupture during their expected life time such as: age, medical comorbidities, history of smoking, intracranial aneurysm size, location, and morphology, family history, history of prior asymptomatic subarachnoid hemorrhage (aSAH), documented growth of intracranial aneurysm on serial imaging, presence of multiple intracranial aneurysms, and presence of concurrent pathology. The benefits of device use may not outweigh the risks associated with the device in certain patients; therefore, judicious patient selection is recommended. This device has not been evaluated for pediatric use. The safety and effectiveness of the device has not been established in the treatment of small and medium wide-neck intracranial aneurysms. Experience with endovascular implants indicates that there is a risk of stenosis. Subsequent stenosis may require dilatation of the vessel segment containing the device. The risks and long-term outcomes following dilatation of endolethelialized devices is unknown at present. A thrombosing aneurysm may aggravate pre-existing or cause new symptoms of mass effect and may require medical therapy. Operators should take all necessary precautions to limit X-radiation dose to patients and themselves by using sufficient shielding, reducing fluoroscopy times, and modifying X-ray technical factors where possible. Lower intracranial aneurysm occlusion rates may be associated with giant intracranial aneurysms (≥25mm). Lower intracranial aneurysm occlusion rates may be associated with implants that are not fully apposed to the vessel wall. MRI Safety Information: Non-clinical testing demonstrated that the Surpass Evolve Flow Diverter is MR Conditional for single and overlapping up to 60mm in length. A patient with the Surpass Evolve Flow Diverter may be scanned safely in an MR system under the following conditions: Static magnetic field of 1.5 Tesla and 3 Tesla, only; Maximum spatial gradient magnetic field of 3,000 Gauss/cm (30 T/m); Maximum gradient strength of 250 Gauss/cm (2.5 T/m); Maximum speed of gradient switching of 100 Gauss/cm µsec (10 T/m-µsec); Maximum amplitude of magnetic field gradient of 250 Gauss/cm (2.5 T/m). MRI MR system reported, whole body averaged specific absorption rate (SAR) of 2 W/kg in the Normal Operating Mode; Under the scan conditions defined, the Surpass Evolve Flow Diverter is expected to produce a maximum temperature rise of 3.0°C after 15 minutes of continuous scanning (i.e., per pulse sequence). In non-clinical testing, the image artifact caused by the Surpass Evolve Flow Diverter extends approximately 10mm from this implant when imaged using a gradient echo pulse sequence and a 3 Tesla MR system. The lumen cannot be visualized on gradient echo or T1-weighted, spin echo pulse sequences.

Copyright © 2020 Stryker AP003196 v1.0
STROKE SOLUTION

A NEW ANGLE IN STROKE TREATMENT

Closer to Clot
.088" intracranial access for a position of advantage

Vessel-Matched Catheters
Optimize clot engagement across a range of vessels

Powerful Aspiration
Unique TRX™ Tip combined with -29.5 inHg vacuum

Important Safety Information: Rx Only. The Zoom 88-T Large Distal Platform (Zoom 88-T) is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature. The Zoom Aspiration Catheters (Zoom 71, Zoom 55, Zoom 46, Zoom 35), with the Zoom Aspiration Tubing Set and Zoom Aspiration Pump (or equivalent vacuum pump), are indicated for use in the recanalization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. The Zoom Aspiration Pump is intended for general suction use in hospitals and clinics.

The Zoom Aspiration Tubing Set is intended to connect the Zoom Aspiration Catheter to the Zoom Canister of the Zoom Aspiration Pump and to allow the user to control the fluid flow. The Zoom Canister is intended to collect aspirated fluids for disposal and prevent fluid ingress from damaging the Zoom Aspiration Pump. The Zoom Aspiration Catheters, Zoom Aspiration Pump and Zoom Aspiration Tubing Set should only be used by physicians who have received appropriate training in interventional techniques and treatment of acute ischemic stroke. Only physicians familiar with standard interventional techniques for aspiration catheters and aspiration pumps should use the Zoom Aspiration Tubing.

For complete product information, including indications, contraindications, warnings, precautions and adverse events, see product IFU included in product packaging, contact Customer Service at +1-408-550-7548, CustomerService@ImperativeCare.com or visit bit.ly/2Vx0Qcf.

Data on file at Imperative Care, Inc.